The primary hypothesis is that weekly digital interactions and routine measurement of TEWL
rates and SC hydration levels will promote patient adherence to maintenance ivermectin
therapy and prevent disease relapse. The project will consist of a trial in which thirty
subjects with rosacea receive ivermectin therapy and are randomized to receive either no
intervention, a weekly digital survey to assess patient's attitudes towards ivermectin
therapy, or a portal hydration measurement device that measures TEWL rates and SC hydration
levels. The study team will measure adherence objectively in all groups with electronic
monitors attached to the containers of the ivermectin, which all subjects will be told to use
daily for maintenance therapy. Additionally, the hydration measurement device can transmit
data to an Internet server via a smartphone using Bluetooth technology, thereby allowing
providers to monitor a patient's TEWL rate and SC levels.